#384 - Special episode — Obicetrapib: The CETP inhibitor with cardiovascular benefits and potential Alzheimer's prevention - The Peter Attia Drive Recap

Podcast: The Peter Attia Drive

Published: 2026-03-16

Duration: 3160

Summary

Obicetrapib is attracting attention as a promising CETP inhibitor with potential benefits for cardiovascular health and Alzheimer's prevention, especially in individuals with the ApoE4 allele. It has shown significant reductions in LDL cholesterol, APOB, and LP-little A, and may improve Alzheimer's biomarkers in high-risk populations.

What Happened

Peter Attia delves into the potential of Obicetrapib, a CETP inhibitor that is generating significant interest due to its implications for cardiovascular health and Alzheimer's disease prevention. The drug is under investigation for its ability to reduce LDL cholesterol and APOB, with phase II trials showing a 50% reduction in LDL cholesterol and a 30% reduction in APOB levels. This positions Obicetrapib as a potentially groundbreaking therapy in a field where previous CETP inhibitors have failed due to toxicity or insufficient efficacy.

The Broadway Biomarker Study provides key insights into Obicetrapib's effects, particularly in individuals with the ApoE4 allele, known for its association with increased Alzheimer's risk. The study reported a significant attenuation in the progression of PTAU217, an Alzheimer's biomarker, with a nearly 8% reduction noted in ApoE4E4 individuals compared to placebo. These findings suggest that Obicetrapib may offer dual benefits by addressing both cardiovascular and neurodegenerative disease risks.

Peter Attia highlights the metabolic benefits of Obicetrapib, including its potential to reduce LP-little A by a third and positively remodel HDL particles. This is significant given LP-little A's role as a cardiovascular risk factor, which Obicetrapib addresses while also showing a potentially neutral or favorable impact on diabetes risk, contrasting with the effects of statins.

Obicetrapib's potential extends to the brain, where it may increase APOA1 in the CNS and provide cerebrovascular benefits, particularly for ApoE4 carriers. The brain's lipid transport system, organized around apolipoprotein E, operates separately from the body's circulatory system, making this a critical area of study for Alzheimer's prevention.

The PREVAIL Phase III trial is underway to evaluate Obicetrapib's cardiovascular outcomes. Europe may approve the drug based on biomarker findings, but U.S. approval requires evidence of mortality reduction or major adverse cardiovascular events (MACE).

Peter Attia notes the significant potential of Obicetrapib in altering the landscape of cardiovascular and Alzheimer's disease prevention. The drug's expected launch in Europe by Q4 2026, with U.S. approval following, marks a critical timeline for its entry into the market. Attia expresses excitement about the drug's prospects, given its promising early data and the historical challenges faced by previous CETP inhibitors.

Key Insights